Life Healthcare: 6.1% net margin versus a loss a year ago, but debt and dividend need scrutiny

On 25 May Life Healthcare released its results for the first half of fiscal 2026. Revenue rose 2.3% year on year, EBITDA grew 6.0%, and net margin reached 6.1% versus a loss-making base a year earlier. Net debt remains negative, and trailing dividend yield is 24.0%. In our view, the share looks neutral: strong profit recovery and high dividend yield are balanced by lacklustre revenue growth and uncertainty over dividend sustainability.

Key takeaways

— Revenue grew only 2.3%, providing limited operating leverage

— EBITDA rose 6.0% with margin expanding to 15.6% from 15.0%

— Net margin of 6.1% versus a loss a year ago – profitability restored

— Net debt is negative: net cash of ZAR 540 million, net debt/EBITDA LTM at -0.18

— Dividend yield of 24.0% over 12 months is a key support, but payout needs scrutiny

— Valuation: P/E LTM 2.55 and EV/EBITDA LTM 5.73 – cheap versus history, but portal model sees no upside

Attractiveness

Key figures, ZAR bn

Revenue grew only 2.3%, providing limited operating leverage

In the first half of fiscal 2026, Life Healthcare's revenue reached ZAR 25.4 billion, up 2.3% year on year. This is moderate growth, mainly reflecting organic expansion rather than accelerating momentum. For a company with operating leverage, such a pace does not create significant cost pressure.

The main contribution likely came from key divisions, though details are not in the facts. Importantly, even with modest revenue growth, the company managed to improve operating efficiency, as seen in EBITDA dynamics.

EBITDA rose 6.0% with margin expanding to 15.6% from 15.0%

EBITDA for the first half of fiscal 2026 rose 6.0% year on year, with EBITDA margin expanding to 15.6% from 15.0% a year earlier. The outperformance of EBITDA relative to revenue points to improved cost control or a shift in business mix toward higher-margin segments.

The 0.6 percentage point margin improvement is a positive signal, but it does not offset weak revenue growth. The sustainability of this improvement will depend on the company's ability to keep costs in check amid possible inflation acceleration.

Net margin of 6.1% versus a loss a year ago – profitability restored

Net profit for the first half of fiscal 2026 delivered a 6.1% net margin, compared with a loss and negative margin of -18.1% a year earlier. This is a dramatic improvement, though it largely reflects a low comparison base.

Profit over the trailing twelve months amounted to ZAR 6.855 billion. The recovery in net profit could have been supported by one-off factors such as cost reductions or asset sale gains, but the facts do not confirm this. Without these details, the sustainability of profit remains uncertain.

Net debt is negative: net cash of ZAR 540 million, net debt/EBITDA LTM at -0.18

As of the latest reporting date, Life Healthcare's net debt is negative at ZAR -540 million, meaning the company has a net cash position. The net debt/EBITDA ratio for the trailing twelve months is -0.18. This is a very low leverage level, providing financial flexibility.

During the period, net debt increased by ZAR 4.2 billion compared to the previous reporting date, and by ZAR 0.3 billion over 12 months. The rise in absolute debt while maintaining a negative value is not alarming but warrants attention. Operating cash flow over the trailing twelve months was ZAR 4.4 billion, covering the company's needs.

Dividend yield of 24.0% over 12 months is a key support, but payout needs scrutiny

The dividend yield over the trailing twelve months is 24.0%. This is a very high level, significantly exceeding the key rate and making the stock attractive for income investors. However, such a high yield may indicate that the market is pricing in a risk of dividend cuts.

Our estimate of the current year's dividend is based on trailing twelve-month profit (ZAR 6.855 billion) and an assumed payout ratio. If the company maintains a payout that supports the current yield, the dividend could remain high. However, sustainability depends on the ability to generate free cash flow and the absence of large one-off write-offs.

What could make the dividend smaller: lower profit, higher capital expenditures, or increased debt. With the current net debt/EBITDA ratio at -0.18, the risk of a dividend cut is low, but the company may prefer to allocate funds to development.

Valuation: P/E LTM 2.55 and EV/EBITDA LTM 5.73 – cheap versus history, but portal model sees no upside

Life Healthcare shares trade at P/E LTM of 2.55 and EV/EBITDA LTM of 5.73. These multiples appear low, especially given the profit recovery. However, we lack data on 3-year averages, so we cannot say whether the stock is cheap or expensive relative to its own history.

According to the portal's model, the upside to fair value is 0%. This means the current price already reflects the expected EBITDA growth at the target multiple. The market may be pricing in risks related to profit sustainability or dividend payments.

Valuation on the latest reported figures

Bottom line

Life Healthcare showed a recovery in net profit to a 6.1% margin versus a loss a year ago, while EBITDA rose 6.0% with margin expanding to 15.6%. However, revenue growth was only 2.3%, limiting operating leverage. The company maintains a net cash position, and the 24.0% dividend yield remains a key support factor. Valuation at P/E LTM 2.55 and EV/EBITDA LTM 5.73 appears low, but the portal model sees no upside. Overall, the stock looks neutral: strengths are balanced by weak growth and dividend uncertainty.